| |
 |
Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy (Guest Editor: Dr. Felix Ruckert)]
 |
| |
|
pp.408-410 (3) Authors: Susanne Sebens, Holger Kalthoff |
| |
|
|
| |
|
An Update on Molecular Research of Pancreatic Adenocarcinoma
|
| |
|
pp.411-417 (7) Authors: Christian Krautz, Felix Ruckert, Hans-Detlev Saeger, Christian Pilarsky, Robert Grutzmann |
| |
|
|
| |
|
Combination Therapy for the Treatment of Pancreatic Cancer
|
| |
|
pp.418-426 (9) Authors: William Greenhalf, Amy Thomas |
| |
|
|
| |
|
Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
|
| |
|
pp.427-433 (7) Authors: Simon Rieder, Christoph W. Michalski, Helmut Friess, > Kleeff |
| |
|
|
| |
|
Aptamers: Potential Applications to Pancreatic Cancer Therapy
|
| |
|
pp.434-441 (8) Authors: Kristy L. Rialon, Rebekah R. White |
| |
|
|
| |
|
Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
|
| |
|
pp.442-447 (6) Author: Michael H. Muders |
| |
|
|
| |
|
Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
|
| |
|
pp.448-454 (7) Authors: Hubert G. Hotz, Birgit Hotz, Heinz-Johannes Buhr |
| |
|
|
| |
|
Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials
|
| |
|
pp.455-463 (9) Authors: Marco Falasca, Federico Selvaggi, Richard Buus, Sara Sulpizio, Charlotte E. Edling |
| |
|
|
| |
|
Anti-Angiogenic Agents in Pancreatic Cancer: A Review
|
| |
|
pp.464-469 (6) Authors: Murwarid M. Assifi, Oscar J. Hines |
| |
|
|
| |
|
Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
|
| |
|
pp.470-478 (9) Authors: Nicholas J. Zyromski, Patrick B. White |
| |
|
|
| |
|
Resveratrol and Its Analogues: Promising Antitumor Agents
|
| |
|
pp.479-490 (12) Author: Hai-Liang Zhu |
| |
|
|
